AU-007 is under clinical development by Aulos Bioscience and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData, Phase II drugs for Merkel Cell Carcinoma have a 15% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AU-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AU-007 is development for the treatment of solid tumor, melanoma, renal cell cancer, Merkel cell carcinoma, colorectal cancer, non-small cell lung cancer and urothelial cancer. It acts by targeting the CD25-binding epitopes of interleukin 2 (IL-2), sparing the binding to the CD122/132-binding epitope.
Aulos Bioscience overview
Aulos Bioscience, an ATP company is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. The company is developing unique IL-2 targeting antibodies that it believes have the potential to become best-in-class treatments for solid tumors. Aulos Bioscience is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of AU-007’s drug-specific PTSR and LoA scores, buy the report here.